1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours
- Resource Type
- Source
- Annals of Oncology. 31:S728-S729
- Subject
Oncology medicine.medical_specialty Durvalumab business.industry Internal medicine medicine Dose escalation Hematology First in human Open label business - Language
- ISSN
- 0923-7534